I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Oncology Congresses

Boehringer Ingelheim is committed to addressing some of society’s most challenging healthcare issues. We want to share our knowledge and encourage clinical advances, which is why we maintain a presence at key congresses including ASCO, ELCC, WCLC and ESMO. Find out more about our activities at the following oncology congresses.

ESMO 2018

Find information on Boehringer Ingelheim’s activities at ESMO 2018.

CSCO 2018

Find information on afatinib clinical data, and Boehringer Ingelheim’s activities at CSCO 2018. This website is intended for HCPs outside the US and the UK.

ASCO 2018

Find information on Boehringer Ingelheim's clinical data and activities at ASCO 2018

ELCC 2018

Find information on Boehringer Ingelheim's clinical data and activities at ELCC 2018

Related information

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

About nintedanib

A detailed look at nintedanib’s mechanism of action and the role of angiogenesis in cancer

* Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.

Last updated: May 2018